Venture Funding Keeps A Steady Pace In Q1
At $7.94bn, the first quarter of 2026 fell only slightly below the $8.04bn in venture capital raised by biopharma companies in Q4 of 2025, which was the biggest quarter in years.
Scrip - April 6, 2026

Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno
Building a portfolio led by three first-in-class potential blockbuster products drove Neurocrine’s willingness to pay a premium to get Vykat XR, which may not face any imminent competition.
Scrip - April 6, 2026

Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version
The company announced topline results showing efficacy consistent with the I.V. version, with convenience likely to be a competitive factor versus Viridian’s elegrobart and veligrotug.
Scrip - April 6, 2026

Pipeline Watch: Thirteen Approvals And Eighteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026

Neurocrine Takes ‘Sensible Way Into Metabolic Disease’ With $2.9bn Soleno Buy
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026

BCI Maker Epia Neuro Bets On ‘Intent-Driven’ Rehab For Stroke Patients With Implant, Glove
Epia Neuro is developing an implantable BCI that is paired with a motorized glove to help stroke survivors regain hand function. The device is designed for standard rehabilitation and long-term use at home.
Medtech Insight - April 6, 2026

US FDA Warning Letters - February-March 2026
Nine companies received US FDA warning letters in February and March 2026, including Avertix Medical, Exactech and Flextronics.
Medtech Insight - April 6, 2026

Philips Recalls Thousands Of X-Ray Systems Due To ‘Device Design’ Malfunction
The US FDA attributes a Philips recall of more than 20,000 fluoroscopy systems to device design. Philips says it is installing corrective measures to address the problem.
Medtech Insight - April 6, 2026

EMA Explains How To Use ‘Emerging’ 3D Printing Technology For Solid Oral Drugs
EMA says 3D printing is an emerging technology with great potential in pharmaceutical applications.
HBW Insight - April 7, 2026

Ingredient Amounts OK On NAD+ Supplement Label, In Advertising Not So Much
Iron Rock Ventures’ Supplement Facts Label information for its thinbi NAD+ supplement doesn’t violate FDA regulations, but National Advertising Division attorneys submit their questions about its advertising ingredient claims to federal and state regulators.
HBW Insight - April 7, 2026

Europe’s Beauty Leaders Sound Alarm Over Regulatory Roadblocks To Innovation
The Value of Beauty Alliance, a collaboration of 17 personal care and beauty companies, met with European lawmakers March 17 urging them to remove regulatory red tape that is hampering R&D and making the EU less competitive.
HBW Insight - April 7, 2026

Xbrane Delays Refiling Ranibizumab Biosimilar With US FDA To Late Spring
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026

Henlius Targets Phesgo With Next-Wave Biosimilar Strategy
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026

Thermo Fisher Accelerates Biosimilars Race With New Platform
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026

BioBytes: Evogene Bets On Autonomous Small-Molecule Discovery
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026

HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026